{"filing":{"accession_number":"0001193125-26-332767","cik":"0001756262","ticker":"TMDX","company_name":"TransMedics Group, Inc.","form":"8-K","filing_date":"2026-08-04","report_date":"2026-08-04","primary_document":"tmdx-20260804.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1756262/000119312526332767/tmdx-20260804.htm"},"events":[{"id":23890,"run_id":21607,"accession_number":"0001193125-26-332767","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"TransMedics issued a press release on August 4, 2026 announcing financial results for the quarter ended June 30, 2026, disclosing total revenue of $189.9 million (21% increase YoY), net income of $14.7 million ($0.41 per diluted share), and raising full-year 2026 revenue guidance to $737–$757 million. This is a standard quarterly earnings release furnished under Item 2.02 and attached as Exhibit 99.1.","company_name":"TransMedics Group, Inc.","ticker":"TMDX","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":24246,"accession_number":"0001193125-26-332767","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"TransMedics issued a press release on August 4, 2026 announcing financial results for the quarter ended June 30, 2026, disclosing total revenue of $189.9 million (21% increase YoY), net income of $14.7 million ($0.41 per diluted share), and raising full-year 2026 revenue guidance to $737–$757 million. This is a standard quarterly earnings release furnished under Item 2.02 and attached as Exhibit 99.1.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:25:35.295509+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24246,"accession_number":"0001193125-26-332767","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"TransMedics issued a press release on August 4, 2026 announcing financial results for the quarter ended June 30, 2026, disclosing total revenue of $189.9 million (21% increase YoY), net income of $14.7 million ($0.41 per diluted share), and raising full-year 2026 revenue guidance to $737–$757 million. This is a standard quarterly earnings release furnished under Item 2.02 and attached as Exhibit 99.1.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:25:35.295509+00:00","company_name":"TransMedics Group, Inc.","ticker":"TMDX","filing_date":"2026-08-04"}]}